Clorox (CLX) director Matthew Shattock adds deferred stock units

Rhea-AI Filing Summary

Clorox director Matthew J. Shattock reported routine equity-based compensation in the form of deferred stock units. He acquired 506.6101 deferred stock units on March 31, 2026 and 191.2909 units on February 13, 2026, each on a 1-for-1 basis with Clorox common stock.

The units were received through dividend reinvestment and in lieu of quarterly director fees under the Independent Directors' Deferred Compensation Plan and will be settled in Clorox stock after his retirement or other termination of board service. Following these awards, he directly holds 20,126.2673 deferred stock units.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Shattock Matthew J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	506.61	$0.00	--
Grant/Award	Deferred Stock Units	191.291	$0.00	--

Holdings After Transaction: Deferred Stock Units — 20,126.267 shares (Direct)

Footnotes (1)

1. 1-for-1 Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan. The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director. Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.

Key Figures

Deferred stock units granted: 506.6101 units Deferred stock units granted: 191.2909 units Total deferred stock units held: 20,126.2673 units +1 more

4 metrics

Deferred stock units granted 506.6101 units Grant on March 31, 2026 through dividend reinvestment and fees

Deferred stock units granted 191.2909 units Grant on February 13, 2026 through director compensation

Total deferred stock units held 20,126.2673 units Holdings after latest reported grant

Conversion ratio 1-for-1 Each deferred stock unit equals one share of Clorox stock at settlement

Key Terms

Deferred Stock Units, Independent Directors' Deferred Compensation Plan, dividend reinvestment, quarterly director's fees, +1 more

5 terms

Deferred Stock Units financial

"Deferred Stock Units acquired through dividend reinvestment during the fiscal year"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

Independent Directors' Deferred Compensation Plan financial

"Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan."

A deferred compensation plan for independent directors lets outside board members postpone receiving part of their fees or stock awards until a later date, often when they retire or leave the board. Think of it as choosing to put pay into a company-run savings plan that grows and pays out later; it matters to investors because it affects director incentives, future cash or share obligations, and how aligned independent directors are with long-term company performance.

dividend reinvestment financial

"Deferred Stock Units acquired through dividend reinvestment during the fiscal year"

Dividend reinvestment is when the money earned from a company's profit sharing, called dividends, is automatically used to buy more shares of that company instead of being received as cash. This process helps investors grow their holdings over time without extra effort, much like using earned interest to buy more of a savings account. It encourages long-term investment growth by continuously increasing the amount of shares owned.

quarterly director's fees financial

"Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees."

settled 100% in Clorox stock financial

"The Deferred Stock Units will be settled 100% in Clorox stock"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shattock Matthew J

(Last) (First) (Middle)

1221 BROADWAY

(Street)

OAKLAND CALIFORNIA 94612-1888

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CLOROX CO /DE/ [ CLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	02/13/2026		A(2)	V	191.2909		(3)	(3)	Common Stock	191.2909	$0.0000	19,619.6572	D
Deferred Stock Units	(1)	03/31/2026		A(4)		506.6101		(3)	(3)	Common Stock	506.6101	$0.0000	20,126.2673	D

Explanation of Responses:

1. 1-for-1

2. Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan.

3. The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director.

4. Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.

	By Jinho Joo, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Clorox (CLX) director Matthew J. Shattock report?

Matthew J. Shattock reported acquiring deferred stock units as part of his director compensation. He received 506.6101 units on March 31, 2026 and 191.2909 units on February 13, 2026, all tied 1-for-1 to Clorox common stock under a deferred compensation plan.

How many deferred stock units does Matthew J. Shattock hold at Clorox (CLX) after these grants?

After the reported grants, Matthew J. Shattock holds 20,126.2673 deferred stock units. These represent his accumulated director compensation in stock-denominated units, which are scheduled to be settled in Clorox common stock when his board service ends through retirement or other termination.

How were the new Clorox (CLX) deferred stock units to Matthew J. Shattock earned?

The new deferred stock units were earned through dividend reinvestment and by electing to receive quarterly director fees in stock units. Both mechanisms operate under Clorox’s Independent Directors' Deferred Compensation Plan, converting cash-based compensation into equity-linked deferred units for the director.

When will Matthew J. Shattock’s Clorox (CLX) deferred stock units be settled into shares?

The deferred stock units will be settled entirely in Clorox common stock when Matthew J. Shattock retires or otherwise terminates his service as a director. Until then, the units remain deferred, tracking Clorox stock on a 1-for-1 basis as part of his long-term board compensation.

Are Matthew J. Shattock’s Clorox (CLX) deferred stock units considered open-market purchases?

No, the reported deferred stock units are not open-market purchases. They are compensation-related awards, received through dividend reinvestment and in lieu of cash director fees under Clorox’s Independent Directors' Deferred Compensation Plan, rather than discretionary buying or selling in the public market.